SRNE News and Press, Sorrento Therapeutics Inc. From 07/06/21

The Biotech industry has been instrumental in developing treatments for the coronavirus. The sector’s long-term potential remains solid due to the aging populating and the rising cost of healthcare. Wall Street analysts expect biotech stocks Sorrento Therapeutics (SRNE) and Catabasis P...

Scott Gries/Getty Images Entertainment Adding more than a third to the YTD gain of ~42.0%, Sorrento Therapeutics (SRNE) has reached its highest level since mid-March with the biggest one-day gain in nearly five months. On CNBC’s Mad Money, TV personality Jim Cramer briefly mentioned th...

Shares of Sorrento Therapeutics (NASDAQ: SRNE) were up by  10.3% as of 2:02 p.m. EDT Thursday. Although the company hasn't released any news, the increase in new COVID-19 cases in many parts of the world may have investors thinking about the potential for Sorrento's COVI-ST...

Shares of Sorrento Therapeutics (NASDAQ: SRNE) jumped 10.6% on Thursday. The big gain came after the company announced that its COVI-STIX COVID-19 rapid diagnostic test received an official Emergency Use Authorization (EUA) and import license from the Mexican government. Sorrent...

Sorrento Therapeutics ([[SRNE]] +5.8%) announces that it has received EUA approval and import license from Mexico authority for COVI-STIX (COVID-19 Virus Rapid Antigen Detection Test).The company also said that it is establishing a local "Sorrento Mexico Ltd" subsidiary to manage commerc...

Sorrento received official EUA registration and product import license: COFEPRIS EUA registration number “OFICIO: CAS/10720/2021”. Sorrento is establishing its “Sorrento Mexico Ltd” subsidiary to enable commercialization of COVI-STIX™ and future ...

Sorrento is more than just a clinical stage biopharma company developing treatments for COVID, cancer and neurodegenerative diseases. It also generates revenues through contract manufacturing and sales of ZTlido used to treat Postherpetic Neuralgia. However, despite some remarkabl...

Broad multi-year agreement between Sorrento Therapeutics and U.S. Naval Medical Research Unit – No. 3 (NAMRU-3) headquartered in Sigonella, Italy with Laboratory Detachments in Cairo, Egypt, Camp Lemonnier, Djibouti, and Accra, Ghana. Scope includes infectious diseases research...

SvetaZi/iStock via Getty Images Following the conclusion of the enrollment in the U.S.-based mid-stage trial, Sorrento Therapeutics ([[SRNE]] -0.6%) has finished the enrollment in its Phase 2 clinical trial of Abivertinib in hospitalized COVID-19 patients in Brazil.The randomized, double...

Phase 2 US clinical trial of Abivertinib randomized last patient (#96) on 4/07/2021. Phase 2 Brazilian clinical trial of Abivertinib randomized last patient (#400) on 06/20/2021. Studies are complementary and address both dose duration and disease stage variations. Data from b...